BRAF and metastatic neoplasm: This important result suggests that the prognostic power associated with the pred-BRAFm signature, or indeed the presence of the BRAF mutation itself, is due to shorter survival time because of aggressive disease after relapse in stage IV disease; however, initially, BRAFMT stage II and III patients are not at a higher risk of their early-stage disease progressing to metastatic disease.